Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metasilicate-based alkaline mineral water maintains intestinal homeostasis through GLP2-dependent gut-brain-microbiome system: providing new potential therapy for irritable bowel syndrome

ABSTRACT: Metasilicate-based alkaline mineral water maintains intestinal homeostasis through GLP2-dependent gut-brain-microbiome system: providing new potential therapy for irritable bowel syndrome

PROVIDER: PRJNA949162 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23978649_1.fastq.gz	Fastqsanger.gz
	SRR23978649_2.fastq.gz	Fastqsanger.gz
	SRR23978650_1.fastq.gz	Fastqsanger.gz
	SRR23978650_2.fastq.gz	Fastqsanger.gz
	SRR23978651_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Metasilicate-based alkaline mineral water maintains intestinal homeostasis through GLP2-dependent gut-brain-microbiome system: providing new potential therapy for irritable bowel syndrome

Project description:To explore the difference in gene expression in the small intestine of weaned piglets who metasilicate-based alkaline mineral water or basic water.

2023-03-31 | GSE228262 | GEO

Transcription profiling of mucosa from human patients with irritable bowel syndrome or ulcerative colitis

Project description:IBS: Patients who have undergone a diagnostic program for gastrointestinal symptoms and where the diagnosis irritable bowel syndrome was reached. UC: Patients with well-diagnosed ulcerative colitis

2007-10-02 | E-GEOD-2461 | biostudies-arrayexpress

Gut virome and irritable bowel syndrome

Project description:The intestinal virome in irritable bowel syndrome

| PRJEB40590 | ENA

Colonic proteome signature in immunoproteasome-deficient stressed mice and its relevance for irritable bowel syndrome

Project description:A role for immunoproteasome in the regulation of intestinal permeability has been previously suggested both in mice during water avoidance stress (WAS) and in patients with irritable bowel syndrome (IBS). We thus aimed (i) to evaluate the colonic proteome in wild-type (wt) and β2i immunoproteasome subunit knock-out (β2i-/-) mice during WAS and (ii) to investigate the colonic expression of 49 ubiquitinated-proteins in diarrhea-predominant IBS patients (IBS-D).

2018-12-05 | PXD011199 | Pride

Fecal microbiota transplantation in irritable bowel syndrome patients

Project description:Fecal microbiota transplantation in irritable bowel syndrome patients

| PRJEB65418 | ENA

A preclinical model of irritable bowel syndrome driven by CHRM3 activation

Project description:Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder that significantly reduces patients' quality of life. However, current animal models have limitations in replicating the complex pathophysiology of IBS. In this study, we successfully developed a mouse model by mating intestinal epithelium-specific Cre tool mice with chemically modified human muscarinic acetylcholine receptor 3 (hCHRM3) mice, resulting in specific expression of the hCHRM3 in the intestinal epithelial cells. Activation of the hCHRM3 with clozapine-N-oxide (CNO) mimicked IBS attacks. The model mice exhibited typical IBS symptoms such as diarrhea, pain, and visceral hypersensitivity, along with pathological changes like intestinal edema and inflammatory cell infiltration, and disruption of the intestinal mucosal barrier. RNA sequencing revealed significant differentially expressed genes between the model and control groups, with KEGG and GO enrichment analyses indicating significant enrichment of immune and inflammation-related pathways. Additionally, the model mice showed increased levels of short-chain fatty acids and imbalances in the diversity and composition of the gut microbiota. This new IBS mouse model effectively simulates the symptoms and pathological processes of human IBS, providing a powerful tool for in-depth research into the pathogenesis of IBS and the development of therapeutic strategies.

2025-02-19 | GSE289595 | GEO

Gut Microbiota in Irritable Bowel Syndrome

Project description:An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota.

| PRJEB40311 | ENA

Genomic and Clinical Effects Associated with a Relaxation Response Mind-Body Intervention in Patients with Irritable Bowel Syndrome and Inflammatory Bowel Disease

Project description:Patients with chronic illnesses such as Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) often have reduced quality of life. IBS is characterized by abdominal pain/discomfort associated with altered bowel function, such as diarrhea or constipation, without gross structural changes or inflammation [1]; IBD is characterized by gross inflammation in the gastrointestinal (GI) tract which can result in symptoms such as abdominal pain, cramping, diarrhea and bloody stools. IBS and IBD can profoundly affect quality of life and are influenced by stress and resiliency.The impact of mind-body interventions (MBIs) on IBS and IBD patients has not previously been examined. In this study IBS and IBD patients were enrolled in a 9-week relaxation response based mind-body group intervention (RR-MBI), focusing on elicitation of the RR and cognitive skill building. We performed Peripheral blood transcriptome analysis to identify genomic correlates of the RR-MBI.

2015-03-12 | GSE66824 | GEO

The gut virome in Irritable Bowel Syndrome

Project description:The gut virome in Irritable Bowel Syndrome differs from that of controls

| PRJEB42420 | ENA

The fecal mycobiome in patients with Irritable Bowel Syndrome

Project description:The fecal mycobiome in patients with Irritable Bowel Syndrome

| PRJEB42375 | ENA